AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 82784 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol, 500 mg twice a day
Number of subjects: 7
Study 30745383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxfendazole (0.5, 1, 3, 7.5, 15, 30, or 60 mg/kg body weight)
Number of subjects: 70
Study 30745383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 28143430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen (10 mg/kg)
Number of subjects: 103
Study 28143430 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (10 mg/kg)
Number of subjects: 103
Study 25818379 — intervention group
Group type: EXPERIMENTAL
Intervention: Indication-based off-label medication order scenarios with lower relative expert power
Number of subjects: 243
Study 25818379 — intervention group
Group type: EXPERIMENTAL
Intervention: Indication-based off-label medication order scenarios with less appropriate prescriptions
Number of subjects: 243
Study 25818379 — intervention group
Group type: EXPERIMENTAL
Intervention: Indication-based off-label medication order scenarios
Number of subjects: 243
Study 23892761 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 20
Study 23892761 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-site probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 20
Study 23892761 — intervention group
Group type: COMPARATOR
Intervention: White light endoscopy (WLE)
Number of subjects: 20
Study 23892761 — intervention group
Group type: COMPARATOR
Intervention: Autofluorescence Imaging (AFI)
Number of subjects: 20
Study 21926932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tualang honey (20 g/d)
Number of subjects: 102
Study 21926932 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy (Femoston 1/5)
Number of subjects: 102
Study 21926932 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 102
Study 21926932 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy
Number of subjects: 102
Study 21926932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tualang honey
Number of subjects: 102
Study 19468011 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 89
Study 19468011 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 89
Study 17018340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation signals (n = 25, treatment group)
Number of subjects: 49
Study 17018340 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 24, devices programmed to remain off)
Number of subjects: 49
Study 12629429 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite physical activity program
Number of subjects: 26
Study 10892932 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 24
Study 10892932 — intervention group
Group type: COMPARATOR
Intervention: High-frequency electrocauter (HF)
Number of subjects: 24
Study 9370848 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothguard
Number of subjects: 80
Study 9370848 — intervention group
Group type: COMPARATOR
Intervention: No Toothguard (Control)
Number of subjects: 80
Study 1286044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (chemotherapy)
Number of subjects: 124
Study 3702214 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (1.6 g/kg body wt)
Number of subjects: 9
Study 3702214 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (0.8 g/kg body wt)
Number of subjects: 9
Study 31589971 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-diagnosis vitamin D levels
Number of subjects: 240
Study 31589971 — intervention group
Group type: COMPARATOR
Intervention: Pre-diagnosis vitamin D levels
Number of subjects: 240
Study 30076447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) delivered with high‐frequency high‐intensity ultrasound
Number of subjects: 15
Study 30076447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27622453 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg every 12 h for 48 h after an initial preoperative dose of parecoxib 40 mg
Number of subjects: 240
Study 27622453 — intervention group
Group type: COMPARATOR
Intervention: Saline every 12 h for 48 h after an initial preoperative dose of saline
Number of subjects: 240
Study 24905068 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval walking (IW)
Number of subjects: 10
Study 24905068 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (IW)
Number of subjects: 10
Study 24905068 — intervention group
Group type: COMPARATOR
Intervention: Continuous walking (CW)
Number of subjects: 10
Study 22428845 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta (IFNβ) treatment
Number of subjects: 172
Study 20660592 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-medication for STI symptoms
Number of subjects: 1601
Study 20660592 — intervention group
Group type: COMPARATOR
Intervention: Work in brothels
Number of subjects: 1601
Study 20660592 — intervention group
Group type: COMPARATOR
Intervention: Awareness of STI services available for FSW
Number of subjects: 1601
Study 18713889 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at Extra-1 point
Number of subjects: 52
Study 18713889 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 52
Study 14984518 — intervention group
Group type: EXPERIMENTAL
Intervention: s(+)-ketamine and morphine
Number of subjects: 28
Study 14984518 — intervention group
Group type: COMPARATOR
Intervention: saline and morphine
Number of subjects: 28
Study 11384629 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d and MPA 2.5 mg/d
Number of subjects: 2673
Study 11384629 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d
Number of subjects: 2673
Study 11384629 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatment groups
Number of subjects: 2673
Study 11384629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2673
Study 8996159 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (P) administered as a 3-hour infusion at dosages of 100 to 250 mg/m2
Number of subjects: 55
Study 8996159 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (C) administered over 30 minutes at dosages of 300 to 400 mg/m2
Number of subjects: 55
Study 8996159 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (P) and Carboplatin (C) administered in different sequences
Number of subjects: 55
Study 8996159 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (P) at doses < 175 mg/m2
Number of subjects: 55
Study 8996159 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (P) at doses >= 175 mg/m2
Number of subjects: 55
Study 8996159 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (P) with P‐T > or = 0.1 mumol/L for < 15 hours
Number of subjects: 55
Study 8996159 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (P) with P‐T > or = 0.1 mumol/L for >= 15 hours
Number of subjects: 55
Study 8485612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilag Estradiol‐TTS (matrix system)
Number of subjects: 530
Study 8485612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciba‐Geigy Estradiol‐TTS (reservoir system)
Number of subjects: 530
Study 2441152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (frusemide)
Number of subjects: 48
Study 2441152 — intervention group
Group type: EXPERIMENTAL
Intervention: Venodilator (isosorbide dinitrate)
Number of subjects: 48
Study 2441152 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriolar dilator (hydralazine)
Number of subjects: 48
Study 2441152 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive inotropic stimulation (prenalterol)
Number of subjects: 48
Study 29948021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus with Metformin (Arm A)
Number of subjects: 24
Study 29948021 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus (Arm B)
Number of subjects: 24
Study 26996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric heart transplantation (PHTx)
Number of subjects: 9837
Study 26996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke after PHTx
Number of subjects: 9837
Study 26996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital heart disease
Number of subjects: 9837
Study 26996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous stroke
Number of subjects: 9837
Study 26996929 — intervention group
Group type: EXPERIMENTAL
Intervention: History of aborted sudden death
Number of subjects: 9837
Study 26996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular assist device
Number of subjects: 9837
Study 26996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation
Number of subjects: 9837
Study 26996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative dialysis
Number of subjects: 9837
Study 26996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection requiring antibiotics before discharge
Number of subjects: 9837
Study 26996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation
Number of subjects: 9837
Study 26996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-treated hypertension
Number of subjects: 9837
Study 24819236 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to vademecum rules (Group two)
Number of subjects: 100
Study 24819236 — intervention group
Group type: COMPARATOR
Intervention: No changes in lifestyle (Group one)
Number of subjects: 100
Study 22051768 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest Pain Unit (CPU)
Number of subjects: 1012
Study 22051768 — intervention group
Group type: COMPARATOR
Intervention: Emergency Department (ED)
Number of subjects: 1012
Study 20833992 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio nuts (53g, 240 cal)
Number of subjects: 59
Study 20833992 — intervention group
Group type: COMPARATOR
Intervention: Refined carbohydrate snack (salted pretzels, 56g, 220 cal)
Number of subjects: 59
Study 19021487 — intervention group
Group type: EXPERIMENTAL
Intervention: Outlook intervention (discussions of end-of-life preparation and completion)
Number of subjects: 82
Study 19021487 — intervention group
Group type: COMPARATOR
Intervention: Attention control (listening to a nonguided relaxation CD)
Number of subjects: 82
Study 19021487 — intervention group
Group type: COMPARATOR
Intervention: True control (no intervention)
Number of subjects: 82
Study 16632462 — intervention group
Group type: EXPERIMENTAL
Intervention: Group VC+ (prior vaginal contraceptive)
Number of subjects: 190
Study 16632462 — intervention group
Group type: COMPARATOR
Intervention: Group VC- (no prior vaginal contraceptive)
Number of subjects: 190
Study 16632462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VC+ and VC-)
Number of subjects: 190
Study 14714835 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental heat-pressed lithium-disilicate glass-ceramic for crowns
Number of subjects: 16
Study 14714835 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental heat-pressed lithium-disilicate glass-ceramic for inlays
Number of subjects: 16
Study 14714835 — intervention group
Group type: COMPARATOR
Intervention: Cementation process
Number of subjects: 16
Study 11019371 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol diphosphate (DES-P) 300 mg daily for 2 weeks
Number of subjects: 49
Study 11019371 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) 100 mg daily for 2 weeks
Number of subjects: 49
Study 11019371 — intervention group
Group type: COMPARATOR
Intervention: None (Control)
Number of subjects: 49
Study 10323113 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg
Number of subjects: 0
Study 10323113 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 10 mg
Number of subjects: 0
Study 10323113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1472669 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire technique for CVC insertion
Number of subjects: 128
Study 1472669 — intervention group
Group type: COMPARATOR
Intervention: De novo catheterization at a different site
Number of subjects: 128
Study 6690656 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding of 24 Cal/oz formula (Similac Special Care)
Number of subjects: 10
Study 6690656 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding of 20 Cal/oz formula (Similac Special Care)
Number of subjects: 10
Study 6690656 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding of 13 Cal/oz formula (Similac Special Care)
Number of subjects: 10
Study 6690656 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding of 6.5 Cal/oz formula (Similac Special Care)
Number of subjects: 10
Study 6690656 — intervention group
Group type: COMPARATOR
Intervention: Feeding of distilled water (0 Cal/oz)
Number of subjects: 10
Study 6690656 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher caloric density feedings
Number of subjects: 10
Study 30649388 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT and neuromuscular exercise (FIT Teens)
Number of subjects: 40
Study 30649388 — intervention group
Group type: COMPARATOR
Intervention: CBT only
Number of subjects: 40
Study 30341990 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1739
Study 30341990 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1739
Study 30341990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1739
Study 30341990 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (both doses)
Number of subjects: 1739
Study 25619411 — intervention group
Group type: EXPERIMENTAL
Intervention: NLFU + SOC (non-contact low-frequency ultrasound therapy combined with standard of care)
Number of subjects: 36
Study 25619411 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 36
Study 25619411 — intervention group
Group type: EXPERIMENTAL
Intervention: NLFU + SOC
Number of subjects: 36
Study 25619411 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 36
Study 24758374 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1790
Study 24758374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumothorax/Hemothorax
Number of subjects: 1790
Study 22226517 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with capecitabine (1000 mg/m² twice daily on days 1 to 14 of each cycle) plus oxaliplatin (130 mg/m² on day 1 of each cycle) for 6 months
Number of subjects: 1035
Study 22226517 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 1035
Study 22226517 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with capecitabine plus oxaliplatin
Number of subjects: 1035
Study 18719041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antipsychotic prescribing (CAP)
Number of subjects: 363
Study 18719041 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-prescribed patients
Number of subjects: 363
Study 17230206 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF) at a subcutaneous daily dose of 10 microg/kg for 5 days
Number of subjects: 0
Study 17230206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17230206 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF)
Number of subjects: 0
Study 15302193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 168
Study 15302193 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 168
Study 12162586 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide 1%, Timolol 0.5%, Betaxolol 0.5%, Brimonidine 0.2%, Latanoprost 0.005% (in healthy volunteers)
Number of subjects: 22
Study 12162586 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5%, Non-selective topical beta receptor blockers, Latanoprost 0.005% (in glaucoma patients)
Number of subjects: 22
Study 9748678 — intervention group
Group type: EXPERIMENTAL
Intervention: Three additional mid biopsies
Number of subjects: 59
Study 9748678 — intervention group
Group type: COMPARATOR
Intervention: Sextant biopsies only
Number of subjects: 59
Study 7936279 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan
Number of subjects: 171
Study 7936279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 3203067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B radiation (UVB) for 8 weeks
Number of subjects: 42
Study 3203067 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 of the minimal erythema dose (MED) of UVB for 8 weeks
Number of subjects: 42
Study 3203067 — intervention group
Group type: COMPARATOR
Intervention: Visible light (placebo) for 8 weeks
Number of subjects: 42
Study 3203067 — intervention group
Group type: COMPARATOR
Intervention: 0.4 of the minimal erythema dose (MED) of UVB for 8 weeks
Number of subjects: 42
Study 31971032 — intervention group
Group type: EXPERIMENTAL
Intervention: BR (Bendamustine and Rituximab)
Number of subjects: 146
Study 31971032 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)
Number of subjects: 146
Study 29747352 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27179257 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional clinic-based therapy + computer-based program (Rannan)
Number of subjects: 26
Study 27179257 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinic-based therapy
Number of subjects: 26
Study 25330012 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy in group I
Number of subjects: 33
Study 25330012 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (group II)
Number of subjects: 33
Study 23900005 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Specific Training Stimulus (RSTS) for 4 weeks followed by 8 weeks of progressive whole-body training (aerobic plus resistance)
Number of subjects: 0
Study 23900005 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise for 4 weeks followed by 8 weeks of progressive whole-body training (aerobic plus resistance)
Number of subjects: 0
Study 20401474 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg per week)
Number of subjects: 12949
Study 20401474 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (2.5 mg/kg per week)
Number of subjects: 12949
Study 20401474 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg per week) in renal cell carcinoma patients
Number of subjects: 12949
Study 20401474 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg per week) in breast cancer patients
Number of subjects: 12949
Study 18712656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 12
Study 17053881 — intervention group
Group type: EXPERIMENTAL
Intervention: ZEEP (zero PEEP)
Number of subjects: 21
Study 17053881 — intervention group
Group type: COMPARATOR
Intervention: PEEP (8 cmH(2)O)
Number of subjects: 21
Study 12812358 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMAL test
Number of subjects: 930
Study 12812358 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 930
Study 12812358 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMAL test for P. falciparum
Number of subjects: 930
Study 12812358 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMAL test for P. vivax
Number of subjects: 930
Study 15327040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis extract (2.5 mg THC and 0.9 mg CBD), dosage escalated from 15 to 30 mg THC over 14 days.
Number of subjects: 57
Study 15327040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 9925088 — intervention group
Group type: EXPERIMENTAL
Intervention: P829 scintigraphy
Number of subjects: 30
Study 8567841 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 0
Study 8567841 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP
Number of subjects: 0
Study 8567841 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone and ATP
Number of subjects: 0
Study 8567841 — intervention group
Group type: COMPARATOR
Intervention: MH61 bead binding
Number of subjects: 0
Study 2107780 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous prostacyclin (epoprostenol)
Number of subjects: 24
Study 2107780 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (anticoagulants, oral vasodilators, and diuretics)
Number of subjects: 24
Study 2107780 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous prostacyclin (epoprostenol) for up to 18 months
Number of subjects: 24
Study 7462528 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 29
Study 7462528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 28189429 — intervention group
Group type: EXPERIMENTAL
Intervention: Current regular aspirin (>3 tablets/week)
Number of subjects: 22071
Study 28189429 — intervention group
Group type: EXPERIMENTAL
Intervention: Past regular aspirin
Number of subjects: 22071
Study 28189429 — intervention group
Group type: EXPERIMENTAL
Intervention: Current postdiagnostic aspirin
Number of subjects: 22071
Study 25431855 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital media application on mobile phones showing inhalation therapy steps
Number of subjects: 66
Study 25431855 — intervention group
Group type: COMPARATOR
Intervention: Written information only
Number of subjects: 66
Study 23545102 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy plus 10 sessions of parasacral transcutaneous electrical neural stimulation (20 minutes, 10 Hz, 700 μs pulse, intensity based on sensitivity threshold, 3 times weekly for 10 sessions)
Number of subjects: 45
Study 23545102 — intervention group
Group type: COMPARATOR
Intervention: Behavioral therapy (control group)
Number of subjects: 45
Study 21419290 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal plus palatal infiltration (1.8 mL buccal + 0.5 mL palatal of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40
Study 21419290 — intervention group
Group type: COMPARATOR
Intervention: Buccal infiltration (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40